<DOC>
	<DOCNO>NCT00040274</DOCNO>
	<brief_summary>The purpose study evaluate DPC 817 . The safety , dosage , body responds drug study .</brief_summary>
	<brief_title>A Study DPC 817 HIV-Infected Males</brief_title>
	<detailed_description>The study consist two part . Patients Part A receive single dose DPC 817 two separate occasion placebo ( solution tablet without drug ) one occasion . Patients Part B receive two separate dos DPC 817 . Patients admit clinical study unit day dose ( Day -1 ) remain least 48 hour take study drug . Patients return clinical study unit Day 8 Day 28 follow dose last treatment period . During study medical medication history take , physical examination , vital sign measurement , routine clinical laboratory test .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIV positive Are male 18 year age ( legal age consent , whichever old ) 55 year age Are female 18 year age ( legal age consent , whichever old ) 55 year age able child ( female may participate Part B ) Have clinically significant finding physical examination clinical laboratory evaluation Have CD4lymphocyte count 50 cells/mm3 Are able willing comply requirement study Exclusion Criteria Patients eligible study : Have opportunistic infection characteristic AIDS Are receive approved experimental HIV drug . Any previous antiHIV treatment must stop least 4 week first dose study medication Are pregnant breastfeeding Are enrolled experimental drug study recieved experimental drug within 30 day first dose study drug Have disease cause problem absorption drug Have active hepatitis Have history pancreatitis peripheral neuropathy Have receive radiation therapy chemotherapy within 30 day first dose study drug Have receive treatment drug affect immune system within 30 day first dose study drug receive HIV immunotherapeutic vaccine Have take prescription overthecounter product within 14 day first dose study drug unless approve doctor Are unable comply dose schedule study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>HIV</keyword>
	<keyword>Phase I</keyword>
</DOC>